Rheumatoid Arthritis Clinical Trial
Official title:
A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe RA Treated With Humira in Greece
Verified date | September 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | Greece: National Organization of Medicines |
Study type | Observational |
The objectives of the study are to observe and assess the long-term use, safety and efficacy of Humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization and to observe compliance of patients with the prescribed treatment.
Status | Completed |
Enrollment | 566 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with moderate or severe active rheumatoid arthritis, who have been prescribed and are receiving Humira (adalimumab) under normal clinical practice for at least one month prior to inclusion and according to the approved Summary of Product Characteristics (SPC) in the European Union. - Patients must be willing to consent to data being collected and provided to Abbott Laboratories. Exclusion Criteria: - Contraindications according to the SPC. - Patients should not participate in another observational Abbott study. |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Greece | Site Reference ID/Investigator# 30116 | A. Glyfada | |
Greece | Site Reference ID/Investigator# 47544 | Ag. Dimitrios, Athens | |
Greece | Site Reference ID/Investigator# 47542 | Ag. Paraskevi, Athens | |
Greece | Site Reference ID/Investigator# 29954 | Agioi Anargyroi | |
Greece | Site Reference ID/Investigator# 29992 | Agioi Anargyroi | |
Greece | Site Reference ID/Investigator# 29915 | Alexandroupoli | |
Greece | Site Reference ID/Investigator# 30118 | Arta | |
Greece | Site Reference ID/Investigator# 29899 | Athens | |
Greece | Site Reference ID/Investigator# 29914 | Athens | |
Greece | Site Reference ID/Investigator# 29944 | Athens | |
Greece | Site Reference ID/Investigator# 29950 | Athens | |
Greece | Site Reference ID/Investigator# 29953 | Athens | |
Greece | Site Reference ID/Investigator# 29989 | Athens | |
Greece | Site Reference ID/Investigator# 30085 | Athens | |
Greece | Site Reference ID/Investigator# 30178 | Athens | |
Greece | Site Reference ID/Investigator# 30472 | Athens | |
Greece | Site Reference ID/Investigator# 30474 | Athens | |
Greece | Site Reference ID/Investigator# 30479 | Athens | |
Greece | Site Reference ID/Investigator# 30480 | Athens | |
Greece | Site Reference ID/Investigator# 30785 | Athens | |
Greece | Site Reference ID/Investigator# 30788 | Athens | |
Greece | Site Reference ID/Investigator# 5284 | Athens | |
Greece | Site Reference ID/Investigator# 30198 | Chalkida | |
Greece | Site Reference ID/Investigator# 29828 | Crete | |
Greece | Site Reference ID/Investigator# 30008 | Crete | |
Greece | Site Reference ID/Investigator# 30210 | Crete | |
Greece | Site Reference ID/Investigator# 30105 | Drama | |
Greece | Site Reference ID/Investigator# 29820 | Elefsina | |
Greece | Site Reference ID/Investigator# 30146 | Ermoupolis Syros | |
Greece | Site Reference ID/Investigator# 30767 | Heraklion Crete | |
Greece | Site Reference ID/Investigator# 30789 | Holargos | |
Greece | Site Reference ID/Investigator# 30482 | Ioannina | |
Greece | Site Reference ID/Investigator# 47322 | Karditsa | |
Greece | Site Reference ID/Investigator# 29850 | Katerini | |
Greece | Site Reference ID/Investigator# 30189 | Kavala | |
Greece | Site Reference ID/Investigator# 30476 | Kifisia | |
Greece | Site Reference ID/Investigator# 30004 | Kozani | |
Greece | Site Reference ID/Investigator# 29993 | Lamia | |
Greece | Site Reference ID/Investigator# 29988 | Larisa | |
Greece | Site Reference ID/Investigator# 30770 | Larissa | |
Greece | Site Reference ID/Investigator# 29922 | Nikea | |
Greece | Site Reference ID/Investigator# 29916 | Patras | |
Greece | Site Reference ID/Investigator# 29972 | Patras | |
Greece | Site Reference ID/Investigator# 29827 | Peristeri | |
Greece | Site Reference ID/Investigator# 29936 | Pyrgos | |
Greece | Site Reference ID/Investigator# 30200 | Rion, Patras | |
Greece | Site Reference ID/Investigator# 29845 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 29900 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 29924 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 29947 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30165 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30192 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30477 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30765 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30791 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30792 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 47543 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 30115 | Trikala | |
Greece | Site Reference ID/Investigator# 30084 | Veria | |
Greece | Site Reference ID/Investigator# 29968 | Xanthi |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, is an event that results in a condition that substantially interferes with the activities of daily living of the participant, is an important medical event requiring medical or surgical intervention to prevent a serious outcome, spontaneous abortion or miscarriage experienced by the participant, or an elective abortion performed on the participant. |
3 years | Yes |
Primary | Disease Activity Score (DAS) 28 Over Time | The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission. | Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Primary | European League Against Rheumatism (EULAR) Response | A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of > 1.2 compared with Baseline and attainment of a DAS28 score of = 3.2. A Moderate EULAR Response is defined as either: an improvement (decrease) in the DAS28 of > 0.6 and = 1.2 from Baseline and attainment of a DAS28 score of = 5.1, or an improvement (decrease) in the DAS28 of > 1.2 from Baseline and attainment of a DAS28 score of > 3.2. No Response is defined as either: an improvement (decrease) in the DAS28 of = to 0.6, or an improvement (decrease) in the DAS28 of > 0.6 and = 1.2 and attainment of a DAS28 of > 5.1. |
Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Primary | Number of Participants With an American College of Rheumatology (ACR) 20 Response | American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 20% improvement in tender joint count; = 20% improvement in swollen joint count; and = 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); Acute phase reactant value (C-reactive protein [CRP]). |
Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Primary | Number of Participants With an American College of Rheumatology (ACR) 50 Response | American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 50% improvement in tender joint count; = 50% improvement in swollen joint count; and = 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); Acute phase reactant value (C-reactive protein [CRP]). |
Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Primary | Number of Participants With an American College of Rheumatology (ACR) 70 Response | American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 70% improvement in tender joint count; = 70% improvement in swollen joint count; and = 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); Acute phase reactant value (C-reactive protein [CRP]). |
Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Secondary | Percentage of Participants Who Missed at Least One Dose of Humira | Compliance to study treatment was measured by the percentage of participants who missed at least one dose of Humira during each time interval between study visits. | Months 3, 6, 9, 12, 18, 24, 30, and 36 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |